BCL2 Family Inhibitors in the Biology and Treatment of Multiple Myeloma
Vikas A Gupta,1 James Ackley,2 Jonathan L Kaufman,1 Lawrence H Boise1 1Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Emory University School of Medicine, Atlanta, GA, USA; 2Cancer Biology Graduate Program, Winship Cancer Institute of Emory University, E...
Main Authors: | Gupta VA, Ackley J, Kaufman JL, Boise LH |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2021-03-01
|
Series: | Blood and Lymphatic Cancer: Targets and Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/bcl2-family-inhibitors-in-the-biology-and-treatment-of-multiple-myelom-peer-reviewed-article-BLCTT |
Similar Items
-
Review of Venetoclax in CLL, AML and Multiple Myeloma
by: Masa Lasica, et al.
Published: (2021-05-01) -
The prognostic impact of t(11;14) in multiple myeloma: A real‐world analysis from the Australian Lymphoma Leukaemia Group (ALLG) and the Australian Myeloma and Related Diseases Registry (MRDR)
by: Kenneth JC Lim, et al.
Published: (2023-08-01) -
Updates in the Use of BCL-2-Family Small Molecule Inhibitors for the Treatment of Relapsed/Refractory Multiple Myeloma
by: Ricardo D. Parrondo, et al.
Published: (2022-07-01) -
Synergistic Effects of Venetoclax and Daratumumab on Antibody-Dependent Cell-Mediated Natural Killer Cytotoxicity in Multiple Myeloma
by: Ayano Nakamura, et al.
Published: (2021-10-01) -
Exploring the current molecular landscape and management of multiple myeloma patients with the t(11;14) translocation
by: Michael D. Diamantidis, et al.
Published: (2022-08-01)